Fc variants with altered binding to FcRn
AssigneeXencor, Inc.
InventorsAaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Life of this patent
Estimating the term…
Abstract
The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
Claims1
A method of increasing antibody serum half-life in a patient comprising administering to said patient an antibody comprising a variant Fc domain as compared to a parent Fc polypeptide, wherein said variant Fc domain comprises a leucine at position 428 and a serine at position 434 in the Fc region of said antibody, wherein said antibody has increased in vivo half-life as compared to an antibody comprising said parent Fc polypeptide, and wherein numbering is according to the EU index in Kabat et al.
Dependencies are inferred from the claim text.